Pfizer

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE182A01018
  • NSEID: PFIZER
  • BSEID: 500680
INR
3,849.40
-0.3 (-0.01%)
BSENSE

Nov 20

BSE+NSE Vol: 14.72 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 970356,
    "name": "Pfizer",
    "stock_name": "Pfizer",
    "full_name": "Pfizer Ltd.",
    "name_url": "stocks-analysis/pfizer",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "3,849.40",
    "chg": -0.3,
    "chgp": "-0.01%",
    "dir": -1,
    "prev_price": "3,849.70",
    "mcapval": "17,496.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 500680,
    "symbol": "PFIZER",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE182A01018",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "14.72 k",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/pfizer-970356-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Pfizer Ltd. Reports Flat Quarterly Financial Trend Despite Record Sales and Profitability",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/pfizer-ltd-reports-flat-quarterly-financial-trend-despite-record-sales-and-profitability-4249671",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/PfizerLtd_fintrenddot_4249671.png",
        "date": "2026-11-04 08:00:25",
        "description": "Pfizer Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has reported its September 2026 quarter results, marking record highs in net sales, profitability, and earnings per share. However, despite these impressive figures, the company’s overall financial trend has shifted from positive to flat, signalling a cautious outlook amid broader market challenges and relative underperformance against benchmarks."
      },
      {
        "title": "Pfizer Ltd. is Rated Sell by MarketsMOJO",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/pfizer-ltd-is-rated-sell-by-marketsmojo-4238698",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/PfizerLtd_mojoScore_4238698.png",
        "date": "2026-10-26 10:10:26",
        "description": "Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 31 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 October 2026, providing investors with the most up-to-date insight into the company’s performance and outlook."
      },
      {
        "title": "Pfizer Ltd. is Rated Sell by MarketsMOJO",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/pfizer-ltd-is-rated-sell-by-marketsmojo-4226580",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/PfizerLtd_mojoScore_4226580.png",
        "date": "2026-10-15 10:10:40",
        "description": "Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 31 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 October 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Markets Rally, But Pfizer Ltd. Sinks to 52-Week Low in Stock-Specific Sell-Off",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/pfizer-ltd-stock-falls-to-52-week-low-of-rs37925-amidst-broad-market-weakness-4218875",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/PfizerLtd_priceRelatedfactors_4218875.png",
        "date": "2026-10-08 10:15:49",
        "description": "While broader indices have shown signs of recovery, Pfizer Ltd. has continued its downward trajectory, hitting a fresh 52-week low of Rs 3,792.5 on 8 Oct 2026. This decline extends the stock’s underperformance relative to the Sensex, which itself is hovering near its own 52-week low but has not fallen as sharply."
      },
      {
        "title": "Pfizer Ltd. is Rated Sell by MarketsMOJO",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/pfizer-ltd-is-rated-sell-by-marketsmojo-4213203",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/PfizerLtd_mojoScore_4213203.png",
        "date": "2026-10-04 10:10:27",
        "description": "Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 31 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 October 2026, providing investors with an up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "Five-Day Slide Pushes Pfizer. to Fresh 52-Week Low of Rs 3,825.9",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/pfizer-stock-falls-to-52-week-low-of-rs38259-amidst-continued-downtrend-4211401",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/Pfizer_priceRelatedfactors_4211401.png",
        "date": "2026-10-01 12:37:17",
        "description": "For the fifth consecutive session, Pfizer. has closed lower, culminating in a new 52-week low of Rs 3,825.9 on 1 Oct 2026. This decline comes amid a broader market downturn, but the stock’s underperformance has been notably sharper, reflecting a complex interplay of valuation concerns and mixed financial signals."
      },
      {
        "title": "Five Consecutive Losses Push Pfizer Ltd. to a New 52-Week Low",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/pfizer-ltd-stock-falls-to-52-week-low-of-rs38815-amidst-continued-downtrend-4209836",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/PfizerLtd_priceRelatedfactors_4209836.png",
        "date": "2026-09-30 10:15:30",
        "description": ""
      },
      {
        "title": "Five Consecutive Losses Push Pfizer Ltd. to a New 52-Week Low",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/pfizer-ltd-stock-falls-to-52-week-low-of-rs392405-amidst-market-downturn-4208817",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/PfizerLtd_priceRelatedfactors_4208817.png",
        "date": "2026-09-29 15:06:28",
        "description": "For the fifth straight session, Pfizer Ltd. closed lower, breaching its 52-week low at Rs 3,924.05 on 29 Sep 2026, marking a significant decline amid broader market weakness."
      },
      {
        "title": "Pfizer Ltd. is Rated Sell by MarketsMOJO",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/pfizer-ltd-is-rated-sell-by-marketsmojo-4202335",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/PfizerLtd_mojoScore_4202335.png",
        "date": "2026-09-23 10:10:46",
        "description": "Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 31 August 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 23 September 2026, providing investors with an up-to-date view of the company’s performance and outlook."
      }
    ],
    "total": 69,
    "sid": "970356",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/pfizer-970356"
  },
  "announcements": [
    {
      "caption": "Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026.",
      "datetime": "03-Nov-2026",
      "details": "Please find enclosed unaudited financial results for the quarter and half year ended September 30 2026 along with the limited review report.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026.",
      "datetime": "26-Oct-2026",
      "details": "Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday November 3 2026 to consider approve and take on record the unaudited financial results for the quarter and half year ended September 30 2026.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "09-Oct-2026",
      "details": "Please find attached Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended September 30 2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Pfizer Ltd. has declared <strong>750%</strong> dividend, ex-date: 17 Jul 26",
          "dt": "2026-07-17",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026.

03-Nov-2026 | Source : BSE

Please find enclosed unaudited financial results for the quarter and half year ended September 30 2026 along with the limited review report.

Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026.

26-Oct-2026 | Source : BSE

Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday November 3 2026 to consider approve and take on record the unaudited financial results for the quarter and half year ended September 30 2026.

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

09-Oct-2026 | Source : BSE

Please find attached Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended September 30 2026.

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Pfizer Ltd. has declared 750% dividend, ex-date: 17 Jul 26

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available